tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships
PremiumRatingsAldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships
27d ago
Aldeyra Resubmits Reproxalap NDA to FDA
Premium
Company Announcements
Aldeyra Resubmits Reproxalap NDA to FDA
1M ago
Aldeyra resubmits topical ocular reproxalap NDA to FDA
Premium
The Fly
Aldeyra resubmits topical ocular reproxalap NDA to FDA
1M ago
Buy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie
PremiumRatingsBuy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie
2M ago
Aldeyra Therapeutics Achieves Success in Phase 3 Trial
Premium
Company Announcements
Aldeyra Therapeutics Achieves Success in Phase 3 Trial
2M ago
Aldeyra’s reproxalap  achieves primary endpoint in Phase 3 dry eye disease trial
Premium
The Fly
Aldeyra’s reproxalap achieves primary endpoint in Phase 3 dry eye disease trial
2M ago
Aldeyra price target lowered to $9 from $11 at BTIG
PremiumThe FlyAldeyra price target lowered to $9 from $11 at BTIG
3M ago
Aldeyra Therapeutics: Promising Pipeline and Strategic Focus Justify Buy Rating Despite FDA Concerns
Premium
Ratings
Aldeyra Therapeutics: Promising Pipeline and Strategic Focus Justify Buy Rating Despite FDA Concerns
3M ago
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Developments and Robust Financial Health
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Developments and Robust Financial Health
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100